# US 2020/0390743 A1 · Methods and Compositions For Improving Outcomes of Cancer Patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390743 A1
- Document ID: US20200390743A1
- Status: Published application
- Kind: A1
- Application number: 16/899,699
- Filed: 2020-06-12
- Published: 2020-12-17
- Earliest claimed: 2019-06-12
- Assignees: Reven IP HoldCo LLC
- Applicants: Reven IP HoldCo LLC
- Inventors: James Ervin; Hendrik J. Van Wyk; Brian D. Denomme; Mariette L. Van Wyk; Peter Pacult; Michael A. Volk; Natalie M. Pizzimenti
- Web page: https://patentgrep.com/patent/US20200390743A1

## CPC

- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/51: Thiamines, e.g. vitamin B1
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides compositions and methods for improving outcomes in cancer patients.

## Claims

### Claim 1

A method of preventing, alleviating, or treating a hypoxia-related disease or condition, comprising administering an effective amount of a composition to a subject in need thereof to improve oxygen transport and thereby elevate blood oxygen levels, wherein the composition comprises:
at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3000 mmol/L when administered to a subject, and
wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.

### Claim 2 (depends on 1)

The method of claim 1, wherein the hypoxia-related disease or condition is cancer, angiogenesis, or an angiogenesis-related disorder.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is a tumor or a solid tumor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, ovarian cancer, colon cancer, lung cancer, non-small cell lung cancer, in situ carcinoma (ISC), squamous cell carcinoma (SCC), thyroid cancer, cervical cancer, uterine cancer, prostate cancer, testicular cancer, brain cancer, bladder cancer, stomach cancer, hepatoma, melanoma, glioma, retinoblastoma, mesothelioma, myeloma, lymphoma, and leukemia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition increases intracellular HCO3− level and thereby promotes hemoglobin affinity for oxygen.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject suffers a blood electrolyte imbalance.

### Claim 7 (depends on 4)

The method of claim 4, wherein the blood electrolyte imbalance is a result of excess acid or bicarbonate.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method comprises elevating pO2 level in the venous blood in the subject.

### Claim 9

A method of treating a subject suffering from a condition characterized by elevated serum calcium, comprising administering an effective amount of a composition to the subject to reduce blood calcium levels, wherein the composition comprises:
at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3000 mmol/L when administered to a subject, and
wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.

### Claim 10

A method of restoring tumor suppressor protein p53 function in a subject, comprising administering an effective amount of a composition to the subject, wherein the composition comprises:
at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.

### Claim 11

A method of suppressing tumor aggression in a subject having a cancer while restoring angiogenesis in healthy tissue of the subject, comprising administering an effective amount of a composition to the subject to increase eNOS and suppress iNOS, wherein the composition comprises:
at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.

### Claim 12

A method of treating a subject having a cancer and suffering from elevated blood glucose related to the cancer, comprising administering an effective amount of a composition to the subject to improve pituitary, thyroid and renal function, thereby reducing blood glucose levels, wherein the composition comprises:
at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.

### Claim 13 (depends on 12)

The method of claim 12, wherein the composition reduces cortisol levels, thereby reducing circulating glucose by relieving mitochondrial stress and endoplasmic reticulum stress.

### Claim 14

A method of inhibiting poly ADP ribose polymerase (PARP), comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises:
at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.

### Claim 15

A method of restoring a disturbed bone marrow microenvironment, comprising administering an effective amount of a composition to a subject in need thereof, the method comprising:
at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.

### Claim 16

A method of promoting apoptosis in cancer, comprising administering an effective amount of a composition to a subject in need thereof, thereby eliciting a temporarily elevated acidic pH in the bloodstream to further decreasing intracellular pH which results in acidic stress and apoptosis in cancer cells, wherein the composition comprises:
at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject is a human or a veterinary subject.

### Claim 18 (depends on 1)

The method of claim 1, wherein the composition is delivered by intravenous, intramuscular, or parenteral administration, oral administration, otic administration, topical administration, inhalation administration, transmucosal administration and transdermal administration.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The method of claim 1, wherein the pharmaceutical grade acid is a physiologically acceptable acid.

### Claim 30 (depends on 1)

The method of claim 1, wherein the pharmaceutical grade acid is hydrochloric acid, ascorbic acid, acetic acid, or a combination thereof.

### Claim 31 (depends on 1)

The method of claim 1, wherein the at least one pH buffering agent is a physiologically acceptable buffer.

### Claim 32 (depends on 1)

The method of claim 1, wherein the at least one pH buffering agent is sodium bicarbonate, a phosphate buffer, sodium hydroxide, an organic acid, an organic amine, ammonia, a citrate buffer, a synthetic buffer creating specific alkaline conditions or a combination thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the synthetic buffer is tris-hydroxymethyl aminomethane.

### Claim 34 (depends on 1)

The method of claim 1, wherein the composition further comprises one or more ingredients selected from the group consisting of vitamins, salts, acids, amino acids or salts thereof, and stabilized oxidative species.

### Claim 35 (depends on 1)

The method of claim 1, wherein the composition further comprises ascorbic acid.

### Claim 36 (depends on 1)

The method of claim 1, wherein the composition further comprises dehydroascorbic acid.

### Claim 37 (depends on 1)

The method of claim 1, wherein the composition further comprises other recognized antioxidant defense compounds including nonenzymatic compounds such as tocopherol (aTCP), coenzyme Q10 (Q), cytochrome c (C) and glutathione (GSH) and enzymatic components including manganese superoxide dismutase (MnSOD), catalase (Cat), glutathione peroxidase (GPX), phospholipid hydroperoxide glutathione peroxidase (PGPX), glutathione reductase (GR); peroxiredoxins (PRX3/5), glutaredoxin (GRX2), thioredoxin (TRX2) and thioredoxin reductase (TRXR2).

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42 (depends on 1)

The method of claim 1, wherein the composition comprises pharmaceutical grade of:
900±90 mg of L-Ascorbic Acid;
63.33±6.33 mg Thiamine HCl;
808±80.8 mg of Magnesium Sulfate;
1.93±0.193 mg of Cyanocobalamin;
119±11.9 mg of Niacinamide;
119±11.9 mg of Pyridoxine HCl;
2.53±0.253 mg of Riboflavin 5′Phosphate;
2.93±0.293 mg of Calcium D-Pantothenate;
840±84 mg of Sodium Bicarbonate;
4.5±0.45 mM of HCl; and
water in an amount to obtain a final composition volume of 20 mL.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)
